Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"

ZHANG Lin; XUE Xiaoqin; HU Yingli; WANG Xihong; LIANG Feng; TANG Ge

doi:10.3969/j.issn.1673-7202.2021.07.018

Suggestions

您当前的位置：

首页 >

文章列表页 >

Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"

Previous: Li Jing's Experience of Treating Digestive Tract Tumor

Next: Professor LYU Renhe's Experience of Clinical Application of Artemisia Capillaris Thunb from the Perspective of "Six Diagnosis and Treatment Principles"

Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"
1.The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
DOI：10.3969/j.issn.1673-7202.2021.07.018

扫描看全文

ZHANG Lin, XUE Xiaoqin, HU Yingli, et al. Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.07.018
DOI：

ZHANG Lin, XUE Xiaoqin, HU Yingli, et al. Treatment of High Risk Idiopathic Membranous Nephropathy Based on "Da Qi"[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails#10.3969/j.issn.1673-7202.2021.07.018 DOI：

摘要

膜性肾病（Membranous Nephropathy，MN）是一种慢性肾脏疾病，发病高峰期在30～50岁，60%～80%膜性肾病表现为肾病综合征。特发性膜性肾病（Idiopathic Membranous Nephropathy，IMN），约占膜性肾病的2/3，根据尿蛋白的量可以分成低危、中危、高危3个等级。中医学认为，“大气”亏虚是高危IMN的发病原因，进而导致“大气”“滞而不运、脱而不升、散而不聚”的病理状态，临床根究“大气”的不同病理状态，可以从“补气清源、活血澄源、固肾复源”3方面来治疗高危IMN，对临床有一定指导意义。

Abstract

Membranous Nephropathy (MN) is a kind of chronic nephritic disease. The peak period of onset is from 30 to 50 years old, and 60% to 80% of membranous nephropathy is characterized by nephrotic syndrome (NS) . Idiopathic Membranous Nephropa-thy (IMN) accounts for about 2/3 of membranous nephropathy. According to the amount of urine protein, it can be divided into three grades: the low, medium and high-risk. TCM holds that "Da Qi" deficiency is the etiology of high-risk IMN, leading "Da Qi" to the pathology of "delay shipment, and do not rise, butnot to get together" . Clinical research on the different pathological states of "Da Qi" shows that high-risk IMN from three aspects of "tonifying qi and clearing the source, promoting blood circulation and clar-ifying the source, and strengthening the kidney and restoring the source", which has certain guiding significance for clinical prac-tice.

关键词

高危特发性膜性肾病大气蛋白尿感染血栓栓塞

Keywords

High riskIdiopathic membranous nephropathyDa QiProteinuriaInfectionThromboembolism

references

杨柳, 刘东伟, 刘章锁. 膜性肾病流行病学研究进展[J]. 中华肾脏病杂志, 2016, 32(3): 229-232.

刘英杰, 张启东, 郭维康, 等. 北京地区单中心2008~2018年特发性膜性肾病流行病学变迁[J]. 临床和实验医学杂志, 2019, 18(2): 181-183.

Hofstra JM, Wetzels JF. Management of patients with membranous ne-phropathy[J]. Nephrol Dial Transplant, 2012, 27(1): 6-9.

于澈, 王荣. 特发性膜性肾病诊疗指南解读[J]. 临床内科杂志, 2015, 32(8): 575-576.

黄智敏, 陈科杰. 环孢素A和环磷酰胺治疗特发性膜性肾病的疗效、复发率及副作用研究[J]. 北方药学, 2016, 13(9): 66.

Stangou M, Marinaki S, Papachristou E, et al. Immunosuppressive reg-imens based on Cyclophospamide or Calcineurin inhibitors: Compari-son of their effect in the long term outcome of Primary Membranous Nephropathy[J]. PLoS One, 2019, 14(8): e0217116

孙洁雨, 郭宏丽, 许静. 钙调磷酸酶抑制剂在儿童难治性肾病综合征中的应用进展[J]. 中国新药杂志, 2018, 27(13): 1515-1520.

苏艳. 特发性膜性肾病治疗反应的影响因素[J]. 深圳中西医结合杂志, 2019, 29(8): 171-173.

Zhang BO, Cheng M, Yang M, et al. Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point[J]. Biomed Rep, 2016, 4(2): 147-152.

李怡然, 解汝娟, 隋满姝, 等. 膜性肾病的临床病理特点及肾小球滤过率下降的危险因素[J]. 临床与病理杂志, 2018, 38(11): 2409-2415.

Yokoyama H, Taguchi T, Sugiyama H, et al. Membranous nephropa-thy in Japan: Analysis of the Japan Renal Biopsy Registry(J-RBR)[J]. Clin Exp Nephrol, 2012, 16(4): 557-563.

张谈, 裘雯慧, 王斌, 等. 张迪蛟“转大气”临床验案四则[J]. 中华中医药杂志, 2011, 26(4): 736-738.

丁英钧, 蔡冀民, 潘莉, 等. 慢性肾脏病“肾络淤阻”共有病机学说及临床意义[J]. 时珍国医国药, 2011, 22(3): 690-691.

支勇, 赵巍, 曹式丽. 曹式丽运用辛通畅络法治疗膜性肾病经验[J]. 中医杂志, 2019, 60(17): 1459-1462.

Ahmed MS, Hou SH, Battaglia MC, et al. Treatment of idiopathic membranous nephropathy with herb Astragalusmembranceus[J]. Am J Kidney Dis, 2007, 50(6): 1028-1032.

Song X, Mo W, Liu X. The NMR solution structure of recombinant RGD-hirudin[J]. Biochem Biophys Res Commun, 2007, 360(1): 103.

金劲松. 水陆二仙丹治疗肾病综合征大鼠蛋白尿的作用机理研究[D]. 武汉: 湖北中医学院, 2007.

余凌, 李惊子, 王海燕, 等. 黄芪当归在肾脏疾病中的应用及其机制研究进展[J]. 中国中西医结合杂志, 2001, 21(5): 396-398.

Song X, Mo W, Liu X. The NMR solution structure of recombinant RGD-hirudin[J]. Biochem Biophys Res Commun, 2007, 360(1): 103.

倪丽, 石咏军, 刘珍珍, 等. 影响特发性膜性肾病患者预后的危险因素分析[J]. 中国中西医结合肾病杂志, 2018, 19(4): 321-323.

陈敬民, 李友娣. 金樱子醇提物对被动型Heymann肾炎大鼠的药理作用研究[J]. 中药材, 2005, 28(5): 408-410.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Experience of CAO Shili for Treatment of Damp-Heat in Proteinuria

LI Ping's Experience of Treating Hepatitis B Virus Associated Glomerulonephritis Through Combined Classic Prescriptions

Discussion on the Syndrome Differentiation and Treatment of Idiopathic Membranous Nephropathy from the Qi Transformation of Triple Energizer

Experience of CAO Shili for Treatment of Damp-Heat in Proteinuria

LI Ping's Experience of Treating Hepatitis B Virus Associated Glomerulonephritis Through Combined Classic Prescriptions

Related Author

No data

Related Institution

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Center for Chinese Medlicine Acupuncture and Moxibustion

Tianjin Medlical University

Beijing University of Chinese Medicine

Institute of Clinical Medicine of China-Japan Friendship Hospital, Beijing Key Laboratory of Immunoinflammatory Diseases

Hubei Academy of Traditional Chinese Medicine

⁰